Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-669/ECHO-304 in first-line recurrent or metastatic head and neck squamous cell carcinoma
2017-001338-24Phase 3Unknown
- Sponsor
- Incyte
- Start
- Oct 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, epacadostat, cetuximab, cisplatin, carboplatin and 1 more in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Incyte. Primary endpoint: Objective response rate. Status: unknown.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-001338-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001338-24.